- antimicrobial resistance, bacterial infection, drug development & delivery, global health, infectious disease, tuberculosis
The Stallings Laboratory studies the molecular pathogenesis of Mycobacterium tuberculosis. Tuberculosis disease results in 1.5 million deaths a year, more than any other single infectious agent. This health crisis is exacerbated by the alarming emergence of multi-drug and extensively drug resistant strains. The inadequacies of present Tuberculosis therapies demand the discovery of new agents to treat M. tuberculosis infection, which requires insight into the pathways involved in M. tuberculosis pathogenesis.
The general approach of our laboratory is to integrate in vivo disease modeling, molecular biology, and biochemistry to provide answers to the fundamental biological questions regarding molecular pathogenesis and yield new therapeutic strategies for the treatment of mycobacterial infections.